Patents Assigned to Senex Biotechnology
-
Patent number: 12281080Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted quinoline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.Type: GrantFiled: May 25, 2021Date of Patent: April 22, 2025Assignees: University of South Carolina, Senex Biotechnology, Inc.Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
-
Publication number: 20210322651Abstract: The invention provides methods for suppressing neointimal formation resulting from vascular surgery, comprising administering to a patient having vascular surgery one or more inhibitors of CDK8/19.Type: ApplicationFiled: December 18, 2015Publication date: October 21, 2021Applicant: Senex Biotechnology, Inc.Inventors: Igor B. Roninson, Taixing Cui
-
Publication number: 20210276956Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.Type: ApplicationFiled: May 25, 2021Publication date: September 9, 2021Applicants: University of South Carolina, Senex Biotechnology, Inc.Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
-
Patent number: 11014906Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted quinoline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.Type: GrantFiled: August 21, 2019Date of Patent: May 25, 2021Assignees: University of South Carolina, Senex Biotechnology, Inc.Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
-
Patent number: 10584369Abstract: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells.Type: GrantFiled: January 13, 2014Date of Patent: March 10, 2020Assignee: Senex Biotechnology, Inc.Inventors: Igor B Roninson, Donald C Porter, Serena Altilia
-
Publication number: 20200062728Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.Type: ApplicationFiled: August 21, 2019Publication date: February 27, 2020Applicants: University of South Carolina, Senex Biotechnology, Inc.Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
-
Publication number: 20200048208Abstract: The invention provides a method for treating a disease or disorder in a mammal which is caused by induced NFkB transcriptional activity in cells of the mammal, the method comprising administering to the mammal a compound that specifically inhibits one or more of CDK8 and CDK19.Type: ApplicationFiled: August 23, 2019Publication date: February 13, 2020Applicant: Senex Biotechnology, Inc.Inventors: Donald C. PORTER, Igor B. RONINSON
-
Patent number: 8598344Abstract: The invention relates to compounds for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.Type: GrantFiled: November 30, 2010Date of Patent: December 3, 2013Assignee: Senex BiotechnologyInventors: Donald C. Porter, Igor B. Roninson, Mark P. Wentland
-
Patent number: 8592147Abstract: The invention relates to methods for high-throughput screening for compounds that modulate cell growth or promoter activity. The invention provides the use of cell lines with properly regulated promoter-reporter expression, suitable for high-throughput screening. More particularly, the invention relates to such screening to identify compounds that affect cell growth and/or that modulate the effect of cell cycle arrest on the function of a promoter that is responsive to cell cycle inhibition.Type: GrantFiled: January 12, 2006Date of Patent: November 26, 2013Assignee: Senex BiotechnologyInventors: Bey-Dih Chang, Igor B. Roninson
-
Publication number: 20120071477Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.Type: ApplicationFiled: November 30, 2010Publication date: March 22, 2012Applicant: Senex Biotechnology, Inc.Inventors: Donald C. Porter, Igor B. Roninson, Mark P. Wentland